538 related articles for article (PubMed ID: 31422205)
21. Association between APOBEC3H-Mediated Demethylation and Immune Landscape in Head and Neck Squamous Carcinoma.
Liu Q; Luo YW; Cao RY; Pan X; Chen XJ; Zhang SY; Zhang WL; Zhou JY; Cheng B; Ren XY
Biomed Res Int; 2020; 2020():4612375. PubMed ID: 32775421
[TBL] [Abstract][Full Text] [Related]
22. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
23. Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach.
Merlano MC; Denaro N; Garrone O
Curr Opin Oncol; 2020 May; 32(3):203-209. PubMed ID: 32195680
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy for Head and Neck Cancer.
Sim F; Leidner R; Bell RB
Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002
[TBL] [Abstract][Full Text] [Related]
25. Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature.
Liu L; Liu Q
Sci Rep; 2024 Apr; 14(1):9914. PubMed ID: 38688945
[TBL] [Abstract][Full Text] [Related]
26. Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
de la Iglesia JV; Slebos RJC; Martin-Gomez L; Wang X; Teer JK; Tan AC; Gerke TA; Aden-Buie G; van Veen T; Masannat J; Chaudhary R; Song F; Fournier M; Siegel EM; Schabath MB; Wadsworth JT; Caudell J; Harrison L; Wenig BM; Conejo-Garcia J; Hernandez-Prera JC; Chung CH
Clin Cancer Res; 2020 Mar; 26(6):1474-1485. PubMed ID: 31848186
[TBL] [Abstract][Full Text] [Related]
27. Subtyping of head and neck squamous cell cancers based on immune signatures.
Song D; Lyu H; Feng Q; Luo J; Li L; Wang X
Int Immunopharmacol; 2021 Oct; 99():108007. PubMed ID: 34332341
[TBL] [Abstract][Full Text] [Related]
28. Immune-related miRNA signature identifies prognosis and immune landscape in head and neck squamous cell carcinomas.
Ma B; Li H; Qiao J; Meng T; Yu R
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33111959
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the immune cell function landscape in head and neck squamous carcinoma to assist in prognosis prediction and immunotherapy.
Wang W; Zhang Z; Li W; Wei D; Xu J; Qian Y; Cao S; Lei D
Aging (Albany NY); 2023 Nov; 15(21):12588-12617. PubMed ID: 37955651
[TBL] [Abstract][Full Text] [Related]
30. Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.
Huang ZD; Liu ZZ; Liu YY; Fu YC; Lin LL; Hu C; Gu HY; Wei RX
Front Immunol; 2021; 12():791621. PubMed ID: 35003112
[TBL] [Abstract][Full Text] [Related]
31. CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.
Wang H; Nan S; Wang Y; Xu C
J Cell Mol Med; 2021 May; 25(10):4596-4607. PubMed ID: 33733587
[TBL] [Abstract][Full Text] [Related]
32. APOBEC Mutagenesis Is Concordant between Tumor and Viral Genomes in HPV-Positive Head and Neck Squamous Cell Carcinoma.
Faden DL; Kuhs KAL; Lin M; Langenbucher A; Pinheiro M; Yeager M; Cullen M; Boland JF; Steinberg M; Bass S; Lewis JS; Lawrence MS; Ferris RL; Mirabello L
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452530
[TBL] [Abstract][Full Text] [Related]
33. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC.
Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q
BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648
[TBL] [Abstract][Full Text] [Related]
34. HNSCC: Tumour Antigens and Their Targeting by Immunotherapy.
von Witzleben A; Wang C; Laban S; Savelyeva N; Ottensmeier CH
Cells; 2020 Sep; 9(9):. PubMed ID: 32942747
[TBL] [Abstract][Full Text] [Related]
35. TNF Patterns and Tumor Microenvironment Characterization in Head and Neck Squamous Cell Carcinoma.
Long Q; Huang C; Meng Q; Peng J; Yao F; Du D; Wang X; Zhu W; Shi D; Xu X; Qi X; Deng W; Chen M; Li Y; Yang A
Front Immunol; 2021; 12():754818. PubMed ID: 34691075
[TBL] [Abstract][Full Text] [Related]
36. The Immune Infiltration in HNSCC and Its Clinical Value: A Comprehensive Study Based on the TCGA and GEO Databases.
Sun X; Zhang L; Liu S
Comput Math Methods Med; 2021; 2021():1163250. PubMed ID: 34790249
[TBL] [Abstract][Full Text] [Related]
37. The head and neck cancer genome in the era of immunotherapy.
Wijetunga NA; Yu Y; Morris LG; Lee N; Riaz N
Oral Oncol; 2021 Jan; 112():105040. PubMed ID: 33197752
[TBL] [Abstract][Full Text] [Related]
38. Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma.
Zhou Q; Yuan O; Cui H; Hu T; Xiao GG; Wei J; Zhang H; Wu C
Front Cell Infect Microbiol; 2022; 12():1007950. PubMed ID: 36425786
[TBL] [Abstract][Full Text] [Related]
39. An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation.
Fu Y; Tian G; Li J; Zhang Z; Xu K
Int J Mol Med; 2020 Oct; 46(4):1501-1513. PubMed ID: 32700748
[TBL] [Abstract][Full Text] [Related]
40. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]